TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00944944

Intervention type: BEHAVIORAL
Intervention: limb volume measurements and GCLQ lymphedema symptom assessment questionnaire
Description: Upon obtaining consent, the participants without a history of lower extremity lymphedema will be asked to undergo limb volume measurements to ensure the accuracy of group assignment to the nonlymphedema group. Participants will then be asked to complete the one time GCLQ lymphedema symptom assessment questionnaire. The survey tool and Limb volume (LV) data and feedback from participants about the GCLQ will be collected. We expect the study survey to take approximately 5-10 minutes to complete and 5-10 minutes to collect LV data.

Intervention type: BEHAVIORAL
Intervention: GCLQ lymphedema symptom assessment questionnaire
Description: The gynecologic cancer survivors with lymphedema group will have documented lower extremity lymphedema. Participants will be asked to complete a one time assessment, the Gynecologic Cancer Lymphedema Questionnaire to identify lower extremity lymphedema symptoms in gynecologic cancer survivors. They will also be asked to provide feedback about their satisfaction with and the feasibility of the GCLQ as a brief assessment tool that could be used in the clinical care setting.
Study: NCT03665155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-daratumumab
Description: 2 mCi of 89Zr-daratumumab will be administered on day 0.
Study: NCT01601977

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Non-invasive ventilation with standard ventilator
Study: NCT01566825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: amitriptyline 25 mg at 9:30 pm, day 10, and 50 mg at 1:30 am, day 11

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo(white 8 mm Lichtenstein®) at 9:30 pm, day 10, and at 1:30 am, day 11
Study: NCT03665155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT scans
Description: PET/CT images will be obtained on post-administration days 1, 2-4, 5-6, and/or 7-8 following administration of 89Zr-DFO-daratumumab to determine the optimal time point for imaging.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws
Description: Blood and serum samples will be weighed and counted in a scintillation well counter calibrated for 89Zr. Immediately before or after each PET/CT imaging session,
Study: NCT01104272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LipoSonix (Ultrasound treatment of Subcutaneous Adipose Tissue)
Description: Study of Adipose Tissue Treatment Using Focused Ultrasound
Study: NCT01186419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD602 (FBS0701, SSP-004184)
Description: Oral FBS0701 taken one time daily for up to 96 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD602 (FBS0701, SSP-004184)
Description: Oral FBS0701 taken one time daily for up to 96 weeks.
Study: NCT02696577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose aspirin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3
Study: NCT02450474

Intervention type: DEVICE
Group type: OTHER
Intervention: Intermittent pneumatic compression device
Description: Flowtron, Circulation Booster and Sports XL devices will be used.

Intervention type: DEVICE
Group type: OTHER
Intervention: Intermittent pneumatic compression device
Description: Flowtron, Circulation Booster and Sports XL devices will be used.

Intervention type: DEVICE
Group type: OTHER
Intervention: Neuromuscular electrical stimulation
Description: Flowtron, Circulation Booster and Sports XL devices will be used.

Intervention type: DEVICE
Group type: OTHER
Intervention: Neuromuscular electrical stimulation
Description: Flowtron, Circulation Booster and Sports XL devices will be used.
Study: NCT00749632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxybutynin
Description: low dose oxybutynin administered daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxybutynin
Description: middle dose oxybutynin administered daily
Study: NCT03942055

Intervention type: DEVICE
Intervention: Sonosite Edge II Ultrasound
Description: Certified by UAB Biomedical and Clinical Engineering Dept- certification #9365 Mechanism of Action: Point of Care Bedside Ultrasound

Intervention type: DEVICE
Intervention: Sonosite Edge II Ultrasound
Description: Certified by UAB Biomedical and Clinical Engineering Dept- certification #9365 Mechanism of Action: Point of Care Bedside Ultrasound
Study: NCT03923842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab Inj 120 MG/1.7ML
Description: Denosumab 120 mg sc on day -15, -8 and day 1, followed by Denosumab 120 mg sc q4wks + platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Denosumab 120 mg sc q4wks will continue for 12 months since chemotherapy end.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy as clinical standard of care
Description: platinum based drugs q3wks + Gemcitabine 1250 mg/sm day 1,8 q3wks for 6 cycles. Gemcitabine will continue for 12 months if the patient will not shown disease progression
Study: NCT01078545

Intervention type: DRUG
Intervention: Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)
Description: Leuprolide acetate 11.25 mg every 3 months sc or im, number of injections during the trial - 5 in Poland, Leuprolide acetate 3.75 mg every 1 month sc or im, number of injections during the trial - 12 in Ukraine.
Study: NCT01171573

Intervention type: PROCEDURE
Intervention: Venepuncture
Description: Venepuncture - Taking blood

Intervention type: PROCEDURE
Intervention: Venepuncture
Description: Venepuncture - Taking blood
Study: NCT02497755

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App for smartphone
Description: A smartphone app will send psychoeducation and reminders to patients to complete self-report data, will collect passive data, and will provide aggregated information to a provider dashboard.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: smartphone
Study: NCT03052673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 1mcg/kg will be given at induction of anaesthesia followed by intraoperative infusion of 0.5 mcg/kg/hr in both the arms . Postoperatively IV-PCA pump containing fentanyl will be attached to patients in both the arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl 1mcg/kg will be given at induction of anaesthesia followed by intraoperative infusion of 0.5 mcg/kg/hr in both the arms . Postoperatively IV-PCA pump containing fentanyl will be attached to patients in both the arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ketamine
Description: Ketamine 0.5 mg/kg will be given post-induction of anaesthesia followed by infusion of 0.5 mcg/kg /hr in the Ketamine + Fentanyl group arm
Study: NCT00514917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m\^2 intravenous infusion over 1 hour every 3 weeks up to 10 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: 22.5 mg injection subcutaneously every 12 weeks up to 18 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide
Description: 22.5 mg injection subcutaneously every 12 weeks up to 18 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: 50 mg tablet orally once daily for first 4 weeks of treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: 50 mg tablet orally once daily for first 4 weeks of treatment.
Study: NCT03556176

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Three exercises sessions - 30 min (light: 45 - 50%, moderate: 65 -70% and vigorous: 85 - 90% Heart Rate Maximal).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Three exercises sessions - 30 min (light: 45 - 50%, moderate: 65 -70% and vigorous: 85 - 90% Heart Rate Maximal).
Study: NCT00749632

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxybutynin
Description: high dose oxybutynin administered daily
Study: NCT03045146

Intervention type: OTHER
Intervention: Multimodal brain imaging
Description: Comparison of the Rate of Good Neurological Functional Outcome defined by Modified Rankin Scale 0-2, 3 Months after an acute ischemic stroke treated by thrombectomy according to the presence or not of a Target Mismatch on Baseline imaging (MRI or CTP).
Study: NCT04350515

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyberball: Other Exclusion
Description: A cyberball paradigm, whereas 2 avatars and the subject are playing a virtual ball tossing game. In this condition, one of the avatars is excluded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cyberball: Player Exclusion
Description: A cyberball paradigm, whereas 2 avatars and the subject are playing a virtual ball tossing game. In this condition, the subject is excluded by the avatars.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness: Emotion Regulation Task
Description: In this task, subjects listen to an audio file containing a scripted emotion regulation exercise. This exercise is based by the authors Nissen \& Sturm (2018). It takes around 14 minutes to complete the whole task.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness: Emotion Regulation Task
Description: In this task, subjects listen to an audio file containing a scripted emotion regulation exercise. This exercise is based by the authors Nissen \& Sturm (2018). It takes around 14 minutes to complete the whole task.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness: Word Recognition Task
Description: In this task, subjects listen to an audio file containing a scripted word recognition exercise. It contains both contrary words recognition (e.g. The opposite of loud is ...) and completion of german sayings (e.g. That's where the dog is...). It takes around 14 minutes to complete the whole task.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness: Word Recognition Task
Description: In this task, subjects listen to an audio file containing a scripted word recognition exercise. It contains both contrary words recognition (e.g. The opposite of loud is ...) and completion of german sayings (e.g. That's where the dog is...). It takes around 14 minutes to complete the whole task.
Study: NCT02037945

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 18F-FCH PET Scan
Study: NCT02158533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose ALKS 5461
Description: Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose ALKS 5461
Description: Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Study: NCT04680923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CPPLAI
Description: In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal 40 ml of sterile water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Description: In this intervention, after general anesthesia patients will receive intraoperative combined periportal and preperitoneal bupivacaine 0.25% 2-3 mg/kg diluted in 40 ml normal saline.
Study: NCT03999970

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sand fly bite
Description: Comparison between sand fly bites from two different species (Phlebotomus papatasi and Phlebotomus duboscqi)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sand fly bite
Description: Comparison between sand fly bites from two different species (Phlebotomus papatasi and Phlebotomus duboscqi)
Study: NCT03244098

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Assistance Program
Description: TAP caregivers will receive an SCI caregiving guidebook, a 1-hour intervention session by an SCI clinician before hospital discharge, and four 1-hour telehealth clinic-to-home visits at 1, 2, 4, and 6 weeks after discharge by the same clinician
Study: NCT03243903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QS-M insulin-free injector
Description: Using QS-M insulin-free injector as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional insulin pen
Description: Using conventional insulin pen as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
Study: NCT03852225

Intervention type: DIAGNOSTIC_TEST
Intervention: Intra-arrest echocardiography
Description: Intra-arrest echocardiography performed by portable ultrasound device during ongoing chest compressions.
Study: NCT03476850

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: QL Block
Description: Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance QL blocks. QL block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Description: Blocks will be performed under the supervision of a regional anesthesia attending experienced in the performance TAP blocks. TAP block will be performed using ropivacaine 0.375% 20ml each side for a total volume of 40cc.
Study: NCT04282577

Intervention type: DIAGNOSTIC_TEST
Intervention: urinary nephrin and alpha one microglobulin
Description: urinary nephrin and alpha one microglobulin are biomarkers of glomerular filtration barrier injury and tubular injury respectively measured by ELISA

Intervention type: DIAGNOSTIC_TEST
Intervention: urinary nephrin and alpha one microglobulin
Description: urinary nephrin and alpha one microglobulin are biomarkers of glomerular filtration barrier injury and tubular injury respectively measured by ELISA
Study: NCT03556176

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quiet rest
Description: Quiet rest during 30 min

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Quiet rest
Description: Quiet rest during 30 min
Study: NCT00016302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally
Study: NCT00208468

Intervention type: DEVICE
Group type: OTHER
Intervention: European Hip
Description: A cementless femoral component for use in total hip replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zweymüller
Description: A cementless femoral component for use in total hip replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CLS Spotorno
Description: A cementless femoral component for use in total hip replacement
Study: NCT02386423

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RESTIFFIC™ Brand Pressure Application System
Description: The device, RESTIFFIC™, was administered intermittently through the course of the study: one-week baseline period without the device (days 1-7), three weeks of initial testing with the device (days 8-28), a subsequent one-week period without the device (days 29-35), and three weeks of subsequent testing with the device (days 36-56).
Study: NCT02842814

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Drug free
Description: Both Glucocorticoid(GC) and hydroxychloroquine(HCQ) treatment are stopped in stable SLE patients.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCQ
Description: Glucocorticoid(GC) treatment is stopped in stable SLE patients. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC+HCQ
Description: Glucocorticoid(GC) is kept no more than 7.5mg/d. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d.
Study: NCT03157557

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle treatment
Description: Lifestyle treatment
Study: NCT00814710

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine GSK1024850A
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HepB/Hib
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix
Description: Intramuscular injection, 3 doses

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tritanrix-HepB
Description: Intramuscular injection, 3 doses
Study: NCT00484354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium bicarbonate
Description: IV bicarbonate given with amount based on patient weight
Study: NCT00016302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT03769103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Daily oral osimertinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Osimertinib
Description: Daily oral osimertinib

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic radiotherapy
Description: 1-5 fractions of stereotactic radiotherapy
Study: NCT04388475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OKN-007
Description: Drug: OKN-007 (400 mg OKN-007/mL in a phosphate buffer) Administered via IV infusion, at a dose level of 60 mg/kg, given three times a week for 12 weeks, two times a week for a further 12 weeks and once per week until disease progression or up to two years.
Study: NCT00016302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT00484354

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: IV Normal saline with volume given determined by patient weight
Study: NCT04388475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ)
Description: Administered via oral, at a dose level of 150 mg/m2, once daily on Days 1-5 of each 28 day cycle in Cycle 1. If this dose level is tolerated, then in Cycle 2 (and subsequent cycles), at a dose level of 200 mg/m2, once daily on Days 1-5 of each 28 day cycle.
Study: NCT00484354

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bicarbonate
Description: IV bicarbonate, dosed by weight

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline, with volume given based on patient weight
Study: NCT01363050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: Subjects received intranasal ketorolac tromethamine (30 mg) three times daily (t.i.d.) for three days (seven doses in total). Doses were administered every eight hours.
Study: NCT00938548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Pregabalin 75 mg orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vitamin Complex (placebo)
Description: Vitamin Complex orally
Study: NCT04554576

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Disease Self-Management Program (CDSMP) for chronic pain in Spanish
Description: The CDSMP meets for 2.5 hours for 6 weeks. Topics covered are: understanding pain, finding resources, mindfulness, pain science, pacing, exercise, relaxation, communication, sex/intimacy, healthy eating, weight and medication management, making treatment decisions and confronting fears.~Participants are encouraged to create their own personal health goals and make weekly action plans to meet their personal goals. Each week participants learn new tools and problem-solving techniques to meet their health goals and themes are repeated throughout 6-week period to ensure understanding and integration. Participants are encouraged to problem-solve and ask questions to the group about creating and carrying out their self-management plan.~The intervention follows the content of the book Programa de Manejo Personal del Dolor Crónico (Living a Healthy Life with Chronic pain)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self-Management Program (CDSMP) for chronic pain in Spanish
Description: The CDSMP meets for 2.5 hours for 6 weeks. Topics covered are: understanding pain, finding resources, mindfulness, pain science, pacing, exercise, relaxation, communication, sex/intimacy, healthy eating, weight and medication management, making treatment decisions and confronting fears.~Participants are encouraged to create their own personal health goals and make weekly action plans to meet their personal goals. Each week participants learn new tools and problem-solving techniques to meet their health goals and themes are repeated throughout 6-week period to ensure understanding and integration. Participants are encouraged to problem-solve and ask questions to the group about creating and carrying out their self-management plan.~The intervention follows the content of the book Programa de Manejo Personal del Dolor Crónico (Living a Healthy Life with Chronic pain)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote feedback active group
Description: After the 6-week self management program, half the participants will be randomized to an every 6 weeks for 6 months phone or video visit from a health care provider, in Spanish. The phone or video sessions will include: review previous action-plans (goals) and provide support in forming new action-plans (goals)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Remote feedback control group
Description: After the 6-week self-management program, half the participants will be randomized to a control group for 6 months.